Identification of Key Blood Molecular Markers for Immunotherapy

Neoplasms Clinical Trial

Official title:

Identification of Key Blood Molecular Markers for Immunotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00507702
• Other study ID #: VAR0017
• Secondary ID: 97125VAR0017
• Status: Terminated
• Start date: July 6, 2006
• Est. completion date: February 25, 2015

Study information

• Verified date: April 2019
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 191
• Est. completion date: February 25, 2015
• Est. primary completion date: February 25, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.

2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.

3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria:

1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.

2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.

3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Squamous Cell
• Neoplasms
• Squamous Cell Carcinoma

Intervention

Procedure:
• phlebotomy
Standard of care

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy		3 years